{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:14:12Z","timestamp":1773058452555,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Gr\u00fcnenthal B.V."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10067-018-4127-x","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T14:33:15Z","timestamp":1525271595000},"page":"2291-2296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6359-916X","authenticated-orcid":false,"given":"C. A.","family":"Janssen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A. H.","family":"Oude Voshaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. E.","family":"Vonkeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Krol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A. F. J.","family":"van de Laar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"key":"4127_CR1","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK (2011) Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 63:3136\u20133141","journal-title":"Arthritis Rheum"},{"key":"4127_CR2","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liot\u00e9 F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R, American College of Rheumatology (2012) 2012 American college of rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431\u20131446","journal-title":"Arthritis Care Res"},{"key":"4127_CR3","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3899\/jrheum.071229","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, Benjamin KL et al (2009) Quality of life and disability in patients with treatment-failure gout. J Rheumatol 36:1041\u20131048","journal-title":"J Rheumatol"},{"key":"4127_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1757-1146-4-13","volume":"4","author":"E Roddy","year":"2011","unstructured":"Roddy E (2011) Revisiting the pathogenesis of podagra: why does gout target the foot? J Foot Ankle Res 4:13","journal-title":"J Foot Ankle Res"},{"key":"4127_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Liot\u00e9 F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76:29\u201342","journal-title":"Ann Rheum Dis"},{"key":"4127_CR6","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","volume":"71","author":"M Doherty","year":"2012","unstructured":"Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, So AK, Bardin T (2012) Gout: why is this curable disease so seldom cured? Ann Rheum Dis 71:1765\u20131770","journal-title":"Ann Rheum Dis"},{"key":"4127_CR7","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/annrheumdis-2011-200801","volume":"71","author":"K Spencer","year":"2012","unstructured":"Spencer K, Carr A, Doherty M (2012) Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis 71:1490\u20131495","journal-title":"Ann Rheum Dis"},{"key":"4127_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","volume":"74","author":"C-F Kuo","year":"2015","unstructured":"Kuo C-F, Grainge MJ, Mallen C, Zhang W, Doherty M (2015) Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 74:661\u2013667","journal-title":"Ann Rheum Dis"},{"key":"4127_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/BOR.0000000000000141","volume":"27","author":"N Nasser-Ghodsi","year":"2015","unstructured":"Nasser-Ghodsi N, Harrold LR (2015) Overcoming adherence issues and other barriers to optimal care in gout. Curr Opin Rheumatol 27:134\u2013138","journal-title":"Curr Opin Rheumatol"},{"key":"4127_CR10","unstructured":"Scheepers LEJM, van Onna M, Stehouwer CDA et al (2017) Medication adherence among patients with gout: a systematic review and meta-analysis. Semin Arthritis Rheum:1\u201314"},{"key":"4127_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1524-4733.2006.00139.x","volume":"10","author":"A Peterson","year":"2007","unstructured":"Peterson A, Nau DP, Cramer J et al (2007) A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10:3\u201312","journal-title":"Value Health"},{"key":"4127_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v034.i02","volume":"34","author":"F Cribari-Neto","year":"2010","unstructured":"Cribari-Neto F, Zeileis A (2010) Beta regression in R. J Stat Softw 34:1\u201324","journal-title":"J Stat Softw"},{"key":"4127_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.11622\/smedj.2016129","volume":"57","author":"FLA Chia","year":"2016","unstructured":"Chia FLA (2016) Poorly controlled gout: who is doing poorly? Singap Med J 57:412\u2013414","journal-title":"Singap Med J"},{"key":"4127_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/BOR.0b013e3282f54d03","volume":"20","author":"MA Becker","year":"2008","unstructured":"Becker MA, Chohan S (2008) We can make gout management more successful now. Curr Opin Rheumatol 20:167\u2013172","journal-title":"Curr Opin Rheumatol"},{"key":"4127_CR15","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s10067-014-2823-8","volume":"35","author":"B McGowan","year":"2016","unstructured":"McGowan B, Bennett K, Silke C, Whelan B (2016) Adherence and persistence to urate-lowering therapies in the Irish setting. Clin Rheumatol 35:715\u2013721","journal-title":"Clin Rheumatol"},{"key":"4127_CR16","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/ard.2007.076232","volume":"67","author":"L Annemans","year":"2008","unstructured":"Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G (2008) Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 67:960\u2013966","journal-title":"Ann Rheum Dis"},{"key":"4127_CR17","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1007\/s10067-017-3840-1","volume":"36","author":"TL Jansen","year":"2017","unstructured":"Jansen TL, Janssen M (2017) The American College of Physicians and the 2017 guideline for the management of acute and recurrent gout: treat to avoiding symptoms versus treat to target. Clin Rheumatol 36:2399\u20132402","journal-title":"Clin Rheumatol"},{"key":"4127_CR18","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/acr.22336","volume":"66","author":"MA Vera De","year":"2014","unstructured":"De Vera MA, Marcotte G, Rai S et al (2014) Medication adherence in gout: a systematic review. Arthritis Care Res 66:1551\u20131559","journal-title":"Arthritis Care Res"},{"key":"4127_CR19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/ard.2007.076182","volume":"67","author":"DH Solomon","year":"2008","unstructured":"Solomon DH, Avorn J, Levin R, Brookhart MA (2008) Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 67:609\u2013613","journal-title":"Ann Rheum Dis"},{"key":"4127_CR20","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1185\/03007990903126833","volume":"25","author":"S Karve","year":"2009","unstructured":"Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC (2009) Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 25:2303\u20132310","journal-title":"Curr Med Res Opin"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4127-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4127-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4127-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T20:00:57Z","timestamp":1556740857000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4127-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["4127"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4127-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,2]]},"assertion":[{"value":"24 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Given the nature of the study, and in accordance with the Dutch Medical Research Involving Human Subjects Act, no approval by the ethical review board, or formal consent, was required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.A.F.J. van de Laar, MD, PhD received consultancy fees from Gr\u00fcnenthal B.V. All other authors declare they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}